Drug Profile
Research programme: Hsp90 inhibitors - Kosan Biosciences
Alternative Names: KOS-2484Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Kosan Biosciences
- Class Benzoquinones; Macrocyclic lactams
- Mechanism of Action HSP90 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 27 Jun 2008 Kosan Biosciences has been acquired by Bristol-Myers Squibb
- 16 Apr 2008 Pharmacodynamics data from a preclinical trial in Cancer presented at the 99th Annual Meeting of the American Association for Cancer Research (AACR-2008) ,